The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Next steps in NSCLC: checkpoint inhibitors plus cellular therapy
Bruna Pellini, MD, Moffitt Cancer Center, Tampa, FL, discusses the past, present and future of checkpoint inhibitors in non-small cell lung cancer (NSCLC). Many advances in NSCLC have been translated from other solid tumors, such as melanoma, where dramatic clinical benefits with checkpoint inhibitor use were initially demonstrated. Dr Pellini talks on the rapid evolution of the field, with a growing number of agents being approved and a shift to use in earlier lines. Checkpoint inhibitors combined with cellular-based therapies are an exciting next step in lung cancer. CAR-T therapy, macrophages, and tumor-infiltrating lymphocytes are all under investigation to boost responses to checkpoint inhibition. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Bruna Pellini, MD has received research support from Bristol Myers Squibb, advisory board/consultant fees from AstraZeneca and Guidepoint, and speaker honoraria from BioAscend and OncLive.
